Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 802 results for "eisai"

Eisai Inc. Launches National Television Advertising Campaign For BELVIQ® (lorcaserin HCl) CIV
BioSpace

Eisai Launches National Television Advertising Campaign for BE...

/PRNewswire/ -- Eisai Inc. today announced the launch of a new national television advertising campaign for BELVIQ (lorcaserin HCl) CIV, an FDA-approved prescription therapy for chronic weight management. The advertisement will air on numerous ... BusinessWeek, 4 days ago
[x]  

67 images for eisai

Asian Hospital & Healthcare Management, 1 week ago
BioSpace, 4 days ago
BioSpace, 4 days ago
Scottrade, 4 days ago
BioSpace, 4 days ago
Yahoo! Finance, 2 weeks ago
Eisai, 1 week ago
4 Traders, 2 weeks ago
Pharma Letter, 2 weeks ago
Pharmaceutical Business Review, 4 weeks ago

Vizag based Eisai Pharma targets to produce 2 billion tablets by 2016

Visakhapatnam based Japanese company Eisai Pharma in Andhra Pradesh is planning to enhance its production capacity to produce 2 billion tablets per annum by the year 2016. According to S.S. Lamba, managing director, Eisai India operations, the ...
 PharmaBiz4 days ago Eisai Pharma to ramp up production  Business Standard1 month ago Eisai Pharma fights filariasis in Vizag district  Business Line2 months ago
4 Traders

Otsuka acquires rights for hematological cancer treatment from Eisai

Otsuka Pharmaceutical Co., Ltd. has announced an agreement with Eisai Inc., a US subsidiary of Eisai Co., Ltd. to acquire rights for the hematological cancer treatment Dacogen and to an enzyme inhibitor, E7727. Otsuka has acquired rights from Eisai ...
 Individual.com1 week ago Eisai Assigns Its Worldwide Exclusive License for DACOGEN® to Otsuka  4 Traders1 week ago Otsuka Acquires Leukemia Drug Dacogen® From Eisai  Asian Scientist2 weeks ago Otsuka gets Eisai's Dacogen rights in US, Canada & Japan  PharmaBiz2 weeks ago
[x]  
Pharmaceutical Business Review

EISAI : CEO Haruo Naito Appointed Knight Commander of British Empire

- (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo , President & CEO: Haruo Naito , "Eisai") announced today that in recognition of his valuable contribution to relations between Britain and Japan , Her Majesty Queen Elizabeth II has appointed ...
 4 Traders3 days ago Eisai CEO Haruo Naito Appointed Knight Commander of British Empire  Sys-Con India3 days ago Eisai Launches New Energy Drink "Joma": "Cast a Spell of Happiness"  BusinessWeek1 week ago Eisai launches new energy drink Joma  Japan Today1 week ago
[x]  
Asian Hospital & Healthcare Management

Eisai Ally H3 Biomedicine To Present SF3B1 Data At AACR 2014

By Estel Grace Masangkay Eisai announced that its collaborator H3 Biomedicine has named its lead investigational drug candidate for its SF3B1 program targeting novel genetic mutations involved in multiple cancers. H3 Biopharmaceutical will ...
 Bioresearch Online1 week ago H3 Biomedicine''s First Lead Candidate Program Targets Novel Genetic Mutations Involved in Multiple Cancers  Asian Hospital & Healthcare Management1 week ago H3 Biomedicine's First Lead Candidate Program Targets Novel Genetic Mutations Involved In Multiple Cancers  TheStreet.com2 weeks ago H3 Biomedicine Inc.'s First Lead Candidate Program Targets Novel Genetic Mutations Involved In Multiple Cancers  BioSpace2 weeks ago
[x]  

Eisai carcinoma treatment granted FDA orphan designation

According to a post on the FDA's website, Eisai's lenvatinib for the treatment of hepatocellular carcinoma has been granted orphan designation. Health Care Industry
 Yahoo! Finance3 weeks ago Orphan designation: Amatuximab, for the: Treatment of malignant mesothelioma  European Medicines Agency4 weeks ago

Eisai And Biogen Idec Collaborate Over Alzheimer's Disease Drugs

By Estel Grace Masangkay Eisai Co., Ltd. and Biogen Idec announced that the companies have entered into collaboration to develop and market two of Eisai's candidates for Alzheimer's Disease (AD), E2609 and BAN2401. E2609 is a β-site amyloid ...
 Bioresearch Online1 month ago Eisai and Biogen Idec collaborate to develop Alzheimer's disease drugs  Individual.com1 month ago

Eisai begins new weight loss medication study Espicom Reports

Espicom's online news service details Eisai's long-term outcomes study into Lorcaserin (Belviq) weight loss medication. Espicom Business Intelligence has just released the first issue of news service, Cardiometabolic Drug News. The lead story ...
 PRWeb1 month ago Eisai Begins CAMELLIA-TIMI 61 Long-term Outcomes Study to Assess Cardiovascular and Metabolic Effects of Lorcaserin HCI CIV in Overweight/Obese...  Pharmacy Choice1 month ago
[x]  

Eisai Announces President And CEO Succession

Eisai Inc . announced the appointment of Yuji Matsue as company chairman and chief executive officer and Shaji Procida as president and chief operating officer, succeeding current President and CEO Lonnel Coats. The appointments will be effective ...
 Pharmaceutical Online1 month ago Eisai President and CEO to Retire  PharmaceuticalProcessing1 month ago

Biogen, Eisai Join Up in Alzheimer's Drug Pact

Biogen Idec ( NASDAQ: BIIB ) may be best known for its multiple sclerosis drugs, but the biotech giant is also giving itself a few more chances to succeed in the high-risk field of Alzheimer's disease therapies. Cambridge, Mass.-based ...
 Motley Fool1 month ago Biogen's Winning Strategy  Seeking Alpha4 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - eisai
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less